BIO Supporting Oxitec’s Experimental Use Permit (EUP) for Biotech Mosquito
September 30, 2021
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and extend of an experimental use permit (EUP) for the OX5034 Aedes aegypti mosquitoes expressing tetracycline Trans-Activator Variant protein. The mosquitoes are proposed to be released in Florida and California to evaluate the efficacy of the mosquitoes as a tool for suppression of wild Aedes aegypti mosquito populations. The release would be an amendment and extension of an EUP authorized in April 2020.
BIO and the American Seed Trade Association submitted comments on USDA-APHIS' proposed exemptions of five types of genetic modifications a plant can contain and be exempt from regulations for the movement of organisms modified or produced through…
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and extend of an experimental use permit (EUP) for the OX5034 Aedes aegypti mosquitoes expressing tetracycline Trans-Activator Variant protein. The mosquitoes are proposed to be released in Florida and California to evaluate the efficacy of the mosquitoes as a tool for suppression of wild Aedes aegypti mosquito populations. The release would be an amendment and extension of an EUP authorized in April 2020.